Now Available:
Download the podcast of Dr. Crues' presentation

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

MSK Video Report:


Dr. John Crues presents "eMRI as a Diagnostic Tool Comparison to Standard MRI and Other Imaging Techniques" at the ISEMIR Conference

Arthritis: Rituximab OK Following Anti-TNF-Associated TB
Rituximab is both safe and effective in rheumatoid arthritis (RA) patients who have had active TB while being treated with a TNF-α inhibitor...

Arthritis: Treating Early RA With Intensive Step-Up Triple-DMARDs is as Good Starting 3 At Once—Perhaps as Effective as Biologics
Intensive triple therapy with conventional DMARDs in early active RA is as effective as a step-up regimen and is as effective as when all 3 drugs are started together, and both approaches can achieve response rates as high as those seen with biologics...

Consumer News: More than Half of US Diabetics Have Arthritis
Arthritis afflicts more than half of diabetes patients in the US, making exercise difficult...

New from PubMed: Incidence and Prevalence of Psoriatic Arthritis
Researchers found geographic variations in the occurrence of PsA, but methodological issues make interpreting epidemiologic data difficult...

BioPharm Business: Osteologix's IND for NB S101 (strontium malonate) to Treat Osteoporosis Accepted by US FDA
The US FDA has accepted Osteologix's IND application for NB S101 (strontium malonate), a dual-acting bone agent, to treat and prevent osteoporosis...

BioPharm Business: Nuon Raises $27 Million to Advance Tranilast Through Phase II Clinical Trials for Autoimmune Diseases
Nuon completed a $27 million series B financing to advance tranilast, its orally available, small-molecule lead compound...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .